The International Myeloma Foundation (IMF) and the EuroFlow consortium introduce a new automated and highly sensitive flow cytometry method for standardized detection of minimal residual disease (MRD) in myeloma patients.
The International Myeloma Foundation (IMF) and the EuroFlow consortium introduce a new automated and highly sensitive flow cytometry method for standardized detection of minimal residual disease (MRD) in myeloma patients.